Lightnews — Scholar-powered news

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · Jul 3

More than proud to be working @nkinl.bsky.social under the great leadership of @thijnbrummel.bsky.social. His achievements in the field of fundamental sciences ✍️🔬are truly amazing! Congrats Thijn🥳

Netherlands Cancer Institute @nkinl.bsky.social · Jun 27

Proud! 💙 Our scientific director Thijn Brummelkamp receives the Spinoza Prize, a prize for scientists who belong to the best researchers worldwide. A wonderful recognition for his groundbreaking research.

Congrats Thijn! 🎉 @thijnbrummel.bsky.social

Full article ➡️ bit.ly/40p4KnK

2

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · May 17

such an impressive book!

1

Reposted by Marleen Kok, MD PhD, NKI

ESMO - European Society for Medical Oncology @myesmo.bsky.social · May 15

#ESMOBreast25: Low baseline tumour infiltrating lymphocytes #TILs and nodal involvement may predict #BreastCancer patients with poor prognosis despite pathological complete response to neoadjuvant chemotherapy.

#ESMODailyReporter has more

🔗 buff.ly/YmxaCJ7

1 1

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · May 15

I just learned a new pathologist joke: “Tumors dont read J Clin Oncol” from Beppe Viale cited by Carsten Denkert. 🧐📔We as researchers oversimplify cancer biology but tumors dont always follow our classifications @myesmo.bsky.social #esmoambassadors #esmobreast25

1

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · May 15

Thanks to Nadia Harbeck 🙏for the following extremely important remarks: 1) we shouldnt aim for using even 2 gene expression test, one expensive test is enough; 2) instead use a dynamic biomarker: Ki67 drop after endocrine tx. @myesmo.bsky.social #esmoambassadors #esmobreast25

1 4

Reposted by Marleen Kok, MD PhD, NKI

Philippe Aftimos, MD @aftimosp.bsky.social · May 14

An enthusiast and militant talk by @marleenkok.bsky.social at #ESMOBreast25 on the importance of studying biomarkers for immunotherapy in breast cancer, highlighting the KN522 example

#ESMOAmbassadors @myesmo.bsky.social

1 3 7

Reposted by Marleen Kok, MD PhD, NKI

Philippe Aftimos, MD @aftimosp.bsky.social · May 14

The path forward for immunotherapy biomarkers in breast cancer by @marleenkok.bsky.social

#ESMOBreast25 #ESMOAmbassadors @myesmo.bsky.social

2 4

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · May 15

Really impressive talk by Davide Massa on prognostic value of TILs together with nodal status in patients with TNBC and pCR. Outcome for TIL low and cN+ is not that good. Would additional treatment help? @myesmo.bsky.social #ESMOBreast25 #ESMOAmbassadors

1 5

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · May 12

Do you want to know the most recent ins and outs in breast cancer research and treatment? Follow us 👇for the coolest news from #ESMOBreast25 #BCSM @myesmo.bsky.social

ESMO - European Society for Medical Oncology @myesmo.bsky.social · May 12

@aftimosp.bsky.social @erikahamilton9.bsky.social @marleenkok.bsky.social @ptarantinomd.bsky.social

4

Reposted by Marleen Kok, MD PhD, NKI

ESMO - European Society for Medical Oncology @myesmo.bsky.social · Apr 17

📢 #ESMOFellowship applications are now open!
The Society is committed to supporting #YoungOncologists in developing high-quality #TranslationalResearch and #ClinicalResearch projects.
📅 Apply by: 29 May 2025
🔗 buff.ly/NN5Y1ol

4 5

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · Apr 15

Very very proud of you my friend. You are a star and fantastic scientist!

Leila Akkari @leilaakkari.bsky.social · Apr 15

Very proud to receive this Ammodo Science Award recognition of our lab’s work the past few years @nkinl.bsky.social @oncodeinstitute.bsky.social 🙏🙏. Big up to my fabulous lab peeps, mentors, colleagues, family and friends for all their support. Looking forward to celebrate altogether on May 7th🥳🤩🥰!

Netherlands Cancer Institute @nkinl.bsky.social · Apr 15

Cancer researcher @leilaakkari.bsky.social receives an Ammodo Science Award for fundamental research. These biannual awards encourage outstanding scientists in their groundbreaking, fundamental research ➡️ t.co/SmXpE10QaS
@ammodoscience.bsky.social

Photo Leila Akkari - ©Florian Braakman

1 2

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · Apr 15

Please donate!🚵🏽‍♂️💵💰
Last year we received a huge grant 🤩from KWF to launch the internat OPTImaL trial to avoid chemo for low stage BC with many immune cells!
We strongly feel that we should do something in return for KWF so we will bike 🚵🏽‍♂️the Alpe d’Huez 💪🏼
www.opgevenisgeenoptie.nl/fundraisers/...

Marleen Kok

Ik doe mee aan Alpe d’HuZes omdat ik geloof dat wij samen kunnen werken aan een wereld waarin je niet meer doodgaat aan kanker, wil jij mij steunen?

www.opgevenisgeenoptie.nl

1

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · Mar 14

Very good talk by famous statistician #SGBCC2025

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · Mar 14

Meredith Regan proposes framework using established criteria for pragmatic clinical trial design, then walks audience thru process using PREPEC. #masterclass #SGBCC2025

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · Mar 13

Thanks @drsgraff.bsky.social for your amazing report of -again- an amzing session #SGBCC2025

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · Mar 13

Marleen Kok @marleenkok.bsky.social had the difficult task of discussing the role of IO in HR+ breast cancer—she focused on ER-low disease, and suggests that we treat as TNBC. #SGBCC2025

5

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · Mar 1

With co-director @vkaklamani.bsky.social of @sabcs.bsky.social we have been working on #SABCS25 program! Stay tuned! Super exciting with stellar line-up of speakers. With @heidefordlab.bsky.social @itsnotpink.bsky.social and many other fantastic faculty members #bcsm

1 2 6

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · Feb 26

Good to see your here @renemedema.bsky.social

René Medema @renemedema.bsky.social · Feb 25

Times they are a changing. Exit X, happy to join a new community on BlueSky @themaximacenter.bsky.social @hetavl.bsky.social

1

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · Feb 25

Looking forward to work as senior editor for the @theaacr.bsky.social journal Clin Cancer Res with this 👇 amazing editor-in-chief. Congrats Tim Yap!

American Association for Cancer Research (AACR) @theaacr.bsky.social · Feb 24

Timothy A. Yap, MBBS, PhD, has been appointed editor-in-chief of the AACR journal Clinical Cancer Research. Dr. Yap is co-director for the AACR/ASCO Methods in Clinical Cancer Research Workshop and a past cochair of the AACR Annual Meeting Clinical Trials Committee. www.aacr.org/about-the-aa...

2

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · Feb 17

Thanks @joris-vd-haar.bsky.social

3

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · Feb 17

We are hiring! www.nki.nl/careers-stud...
@nkinl.bsky.social

Bioinformatician in Breast Cancer Immunology | Netherlands Cancer Institute

www.nki.nl

1 19 42

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · Feb 9

Important editorial in the @thelancet.bsky.social Wrong decisions endanger Health care in the US and worldwide, especially for people who need it the most! Lets unit and speak up!📣 www.thelancet.com/journals/lan...

American chaos: standing up for health and medicine

Withdrawal from WHO and the Paris Agreements. USAID shuttered and aid halted, ceasing health programmes globally. A freeze on US$3 trillion worth of federal grants and loans, jeopardising the function...

www.thelancet.com

1 3

Reposted by Marleen Kok, MD PhD, NKI

E John Wherry @ejohnwherry.bsky.social · Feb 8

This will kill science in the US. This is how China wins. Why is this not on the news? Why are people not more upset about this?

grants.nih.gov/grants/guide...

NOT-OD-25-068: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates

NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates NOT-OD-25-068. OD

grants.nih.gov

7 36 110

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · Feb 7

very important (but negative) trial on cdk46i in mTNBC. huge shout-out to @stolaney1.bsky.social and Shom Goel for conducting this trial👍 @oncoalert.bsky.social #bcsm

Dana-Farber’s Breast Oncology Center @dfcibreastonc.bsky.social · Feb 7

📢 Just published! A phase II study of #abemaciclib for patients with #retinoblastoma-positive, triple-negative #metastatic breast cancer.
🔓https://pubmed.ncbi.nlm.nih.gov/39908010/
@drtimothyerick.bsky.social @nlinmd.bsky.social
@stolaney1.bsky.social

4 5

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · Feb 7

Many good things to say on this story @oncoalert.bsky.social @naturemedicine.bsky.social: 1) serious biomarker work from a pharma-sponsored trial👏👏 2) a tumor historically consid cold 🥶can respond to aPD1 🤩3) we need to redefine ER+ disease to enable personalized treatm✍️

Sherene Loi MD @loisher.bsky.social · Feb 4

summary CM-7FL @oncoalert.bsky.social
@naturemedicine.bsky.social link: rdcu.be/d8Cw4.
Here Nivo ⬆️ pCR rates in high grade HR+ BC. Increasing pCR rates in this subtype is HARD! PD-L1+ & #TIL higher pCR. This study will change how we think about HR+BC- some are immunogenic & need PD-1i with chemo

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial

Nature Medicine - In the CheckMate 7FL trial, neoadjuvant nivolumab and chemotherapy in patients with newly diagnosed, high-risk estrogen receptor-positive breast cancer led to an increased...

rdcu.be

2 3

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · Jan 10

Impressive paper on biomarkers for immunotherapy in RCC! Good to see biomarkers from pharma-sponsored clinical trials!

Toni Choueiri, MD @drchoueiri.bsky.social · Jan 9

Our 1st translational paper in 2025 now in Nature Cancer —summary Figure attached

www.nature.com/articles/s43...

2

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · Jan 3

Interesting paper on neo-antigen specific T cell therapy! Congrats Cell Therapy team @nkinl.bsky.social

Sebastian Klobuch @sklobuch.bsky.social · Jan 3

Just published: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
rdcu.be/d5ptS

Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial

Nature Medicine - In this phase 1 trial of a personalized, neoantigen-specific autologous T cell therapy, BNT221, when given as monotherapy in patients with metastatic melanoma refractory to PD-1...

rdcu.be

2 8